(Q34660424)

3 August 2017

1 reference

title

The challenge of new drug discovery for tuberculosis (English)

1 reference

3 August 2017

0 references

1 reference

Anil Koul

1

1 reference

3 August 2017

Eric Arnoult

2

1 reference

3 August 2017

Nacer Lounis

3

1 reference

3 August 2017

Jerome Guillemont

4

1 reference

3 August 2017

Koen Andries

5

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 January 2011

1 reference

3 August 2017

1 reference

3 August 2017

469

1 reference

3 August 2017

483-490

1 reference

3 August 2017

7331

1 reference

https://scigraph.springernature.com/pub.10.1038/nature09657

3 August 2017

0 references

cites work

The population dynamics and control of tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Global tuberculosis drug development pipeline: the need and the reality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Pharmacokinetic interactions with rifampicin : clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Structural mechanism for rifampicin inhibition of bacterial rna polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

[Tuberculosis and diabetes]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Tuberculosis and diabetes mellitus: convergence of two epidemics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Drugs for bad bugs: confronting the challenges of antibacterial discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Diarylquinolines target subunit c of mycobacterial ATP synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Respiratory ATP synthesis: the new generation of mycobacterial drug targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Tuberculosis - metabolism and respiration in the absence of growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Antibiotics for emerging pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Linezolid for the treatment of multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Intrapulmonary pharmacokinetics of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

The mechanism of action of PA-824: Novel insights from transcriptional profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Three decades of beta-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Bacterial growth and cell division: a mycobacterial perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Interplay between mycobacteria and host signalling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Protein kinase G from pathogenic mycobacteria promotes survival within macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

The pyruvate requirement of some members of the Mycobacterium tuberculosis complex is due to an inactive pyruvate kinase: implications for in vivo growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

The role of the granuloma in expansion and dissemination of early tuberculous infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Tuberculosis: what we don't know can, and does, hurt us.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

The early bactericidal activity of anti-tuberculosis drugs: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Biomarkers for tuberculosis disease activity, cure, and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Mycobacterium tuberculosis and the macrophage: maintaining a balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Microbial phenotypic heterogeneity and antibiotic tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Update on research and development pipeline: tuberculosis vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Structure-activity relationship of truncated analogs of caprazamycins as potential anti-tuberculosis agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Letting sleeping dos lie: does dormancy play a role in tuberculosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE09657

Analysis of the calculated physicochemical properties of respiratory drugs: can we design for inhaled drugs yet?

21 January 2018

1 reference

12 December 2020

Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months

1 reference

12 December 2020

Clinical experience with the combined use of lopinavir/ritonavir and rifampicin

1 reference

12 December 2020

Aerial dissemination of pulmonary tuberculosis.

1 reference

12 December 2020

Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India.

1 reference

12 December 2020

Physicochemical properties of antibacterial compounds: implications for drug discovery

1 reference

12 December 2020

The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module

1 reference

12 December 2020

The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

1 reference

12 December 2020

Streptomycin in experimental tuberculosis: the effects in guinea pigs following infection in intravenous inoculation.

1 reference

12 December 2020

New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades

1 reference

12 December 2020

A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis

1 reference

12 December 2020

Identifiers

DOI

10.1038/NATURE09657

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference